

April 17, 2019

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

**Code: 532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: CADILAHC**

**Re.: Press Release.**

Dear Sir / Madam,

Please find enclosed a copy of press release dated April 17, 2019 titled "Zydus receives final approval from the USFDA for Acetazolamide for Injection".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**DHAVAL N. SONI**  
**COMPANY SECRETARY**



**Encl.: As above**

## **Zydus receives final approval from the USFDA for Acetazolamide for Injection**

*Ahmedabad, 17 April, 2019*

Zydus Cadila has received the final approval from the USFDA to market Acetazolamide for Injection USP (US RLD – Diamox for Injection), 500 mg per single-dose vial. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g. some types of glaucoma), treatment of certain convulsive disorders (e.g. epilepsy) and promotion of diuresis in instances of abnormal fluid retention (e.g. cardiac edema).

The group now has 262 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*